IL13R alpha 2 CAR-T by TCR Cure Biopharma Technology for Glioma: Likelihood of Approval

IL13R alpha 2 CAR-T is under clinical development by TCR Cure Biopharma Technology and currently in Phase I for Glioma.

Dr. Reddy’s and Novartis sign agreement for anti-diabetes products

As per the deal, Novartis Pharma will be responsible for the supply of Galvus and Galvus Met to DRL at a predetermined price. Credit: fizkes/

May 27, 2024

Field Trip And Wesana Make Major Moves | FTRP, WESA

May 9, 2022

Modular nanoparticles developed for targeted drug delivery and neutralizing biological agents

Engineers at the University of California San Diego have developed modular nanoparticles that can be easily customized to target different biological entities such as tumors,

October 31, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.